TECHNOLOGY:
Vespirator-New Class of Breathing Device for COVID-19 and Other Respiratory Care
AFFILIATION:
Legacy US, Inc, Boise, Idaho, United States
TECHNOLOGY SUMMARY
Area:
Technologies for improved delivery of supplemental oxygen
Tech Brief: The VenspiratorTM is a new class of respiratory care that combines the breathing assistance of a ventilator with the safety and portability of a respirator. Treatment with this non-invasive, non-electric, 100% mechanical ventilation device supports the user’s natural breathing and may prevent the need for a ventilator. (www.venspirator.us)
SHOWCASE SUMMARY
FIGURES OF MERIT
Value Proposition: The VenspiratorTM is fast-tracking to impact the healthcare industry, near-term, for COVID-19 prevention and treatment and long-term for other respiratory illnesses. It could also impact military and first responder industries as protection in the field from air-born disease/chemicals/pollutants and the athletic performance industry through VO2max testing, elevation training, and physical therapy. Empirical data will be gathered using Cough Manikins for fluorescent tracking studies measured in vitro. Legacy’s goal is to price VenspiratorTM at the lowest possible point for maximum accessibility, especially in resource-challenged countries. To further reduce costs, Legacy may replace the 304 stainless steel GovReg® body with nylon-reinforced plastic. Legacy intends to maintain a positive, fiscal financial statement that allows for the financial safety and security that will benefit its employees, itself, and society. Legacy expects sales over 10 million units worldwide in the next 18-24 months as the VenspiratorTM + GovReg® Technology has numerous other uses beyond COVID-19. This will be achieved through a combination of contract manufacturing, region-specific licensing deals, and in-house manufacturing. Legacy is collaborating with Professor Hui-Ling Lin, a member of the 2020 World Health Organization Expert Panel of Respiratory Care, and other medical experts and institutions worldwide.